Monoclonal antibodyPhase 3 trialInvestigational
Olaratumab
How it works
Blocks the PDGFR-alpha receptor on cancer cells, slowing tumor growth and progression.
Cancer types
Efficacy
Studies show that patients with metastatic castration-resistant prostate cancer who received olaratumab experienced a significant delay in disease progression.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.